Clinical Trials

38 enrolled

Turcot syndrome, Microsatellite Instability

NCT03071406 2026-03-11

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

50 enrolled 12 charts

Neoplasm Metastasis, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03999749 2026-03-09

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

71 enrolled 9 charts

Melanoma

NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

DermatologicGenitourinaryThoracic

35 enrolled

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

NCT02530463 2026-03-05

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

MyeloidOther hematologic neoplasm

99 enrolled

Leukemia, Myelodysplastic Syndromes

NCT05122546 2026-03-05

CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

31 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT03223155 2026-03-04

COSINR

78 enrolled

Small Cell Lung Carcinoma

NCT04091750 2026-03-03

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

14 enrolled 9 charts

Melanoma

NCT04109729 2026-03-02

Rad2Nivo

39 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT04969887 2026-02-27

MOST-CIRCUIT

240 enrolled

EndocrineNET

Genital Neoplasms, Female, Neuroendocrine Tumors

NCT03033914 2026-02-17

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

82 enrolled

Lymphoid

Hodgkin Disease

NCT03520491 2026-02-17

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

52 enrolled

Phase NA Active not recruiting

Urinary Bladder Neoplasms

NCT04603248 2026-02-12

A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

50 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04963283 2026-02-10

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

48 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03203473 2026-02-06

Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

85 enrolled 17 charts

Kidney Neoplasms

NCT03749018 2026-02-06

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

30 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03789110 2026-02-06

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

30 enrolled 15 charts

Breast

Breast Neoplasms

NCT04884282 2026-02-06

COMBI-TED

105 enrolled

Phase EARLY_PHASE1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

22 enrolled

Phase EARLY_PHASE1 Active not recruiting

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03543969 2026-02-05

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

14 enrolled

Melanoma, Skin Neoplasms

NCT03628209 2026-02-05

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

21 enrolled

Sarcoma

Sarcoma, Osteosarcoma

NCT03543189 2026-01-29

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

44 enrolled

Prostatic Diseases, Prostatic Neoplasms

NCT02919683 2026-01-28

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

30 enrolled 14 charts

Head and Neck Neoplasms

NCT05500092 2026-01-28

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

17 enrolled

Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

NCT02648997 2026-01-26

An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

40 enrolled 14 charts

CNS

Meningioma

NCT03377023 2026-01-22

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

66 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT04126070 2026-01-22

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

60 enrolled

Hormone Sensitive Prostate Cancer

NCT04599140 2026-01-22

SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial

51 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT06715241 2026-01-22

COLIBRI-2

77 enrolled

Gynecologic

LOCALLY ADVANCED CERVICAL CANCERS

NCT03333616 2026-01-21

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

100 enrolled

EndocrineGenitourinary

Penile Neoplasms, Urogenital Neoplasms, Adrenocortical Carcinoma, Carcinoma, Small Cell

NCT04413123 2026-01-21

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

60 enrolled

Carcinoma, Renal Cell

NCT02656706 2026-01-16

Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma

22 enrolled 10 charts

Melanoma

NCT05239533 2026-01-14

Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer

9 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05501054 2026-01-14

Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

50 enrolled

Carcinoma, Renal Cell

NCT03104439 2026-01-12

Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer

84 enrolled

Pancreatic Neoplasms

NCT03025256 2026-01-08

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Phase EARLY_PHASE1 Active not recruiting

71 enrolled

DermatologicThoracic

Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Meningeal Neoplasms, Nevus

NCT02210117 2026-01-07

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

104 enrolled

Carcinoma, Renal Cell

NCT03171025 2026-01-07

Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma

39 enrolled

CNS

Glioblastoma

NCT05504252 2026-01-07

METIMMOX-2

80 enrolled

Adenocarcinoma, Mucinous, Carcinoma, Signet Ring Cell

NCT02989636 2026-01-06

Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma

21 enrolled

Sarcoma

Chordoma

NCT03921684 2026-01-05

Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients

29 enrolled

Rectal Neoplasms

NCT03929029 2026-01-05

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

11 enrolled 11 charts

Melanoma

NCT03884998 2025-12-30

Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

LymphoidOther hematologic neoplasm

27 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04831320 2025-12-30

Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor

46 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05327270 2025-12-26

Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions

18 enrolled

Head and Neck Neoplasms

NCT04729322 2025-12-23

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

15 enrolled

Colorectal Neoplasms

NCT03728361 2025-12-18

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

55 enrolled

EndocrineNETThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT04658147 2025-12-18

Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

31 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04848116 2025-12-18

Spark2

24 enrolled